drugset / Trial / NCT02808793
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AK002
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase 1 study to investigate the safety and tolerability of AK002 in patients with indolent systemic mastocytosis (ISM).
Timeline
- Start
- 2016-06
- Primary completion
- 2018-12
- Completion
- 2018-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | lirentelimab | Monoclonal antibody | — | Intravenous |